Welcome to our dedicated page for Baxter International news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International stock.
Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.
Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.
Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.
Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.
Baxter International (NYSE:BAX) has appointed Dr. David S. Wilkes to its board of directors, enhancing its leadership with his extensive medical and biotech experience. Dr. Wilkes, dean of the University of Virginia School of Medicine, will serve on Baxter’s Quality, Compliance and Technology Committee. Albert P.L. Stroucken is named lead independent director, succeeding Thomas T. Stallkamp, who remains on the board. The changes reflect Baxter's commitment to diversify its board while maintaining experienced oversight. The board now consists of 13 members.
Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.245 per share, payable on April 1, 2021, to shareholders on record as of February 26, 2021. This sets an annual indicative dividend rate at $0.98 per share. Baxter, with over 85 years of experience, focuses on critical care, nutrition, and surgical products, impacting millions globally. The company’s forward-looking statements suggest that future dividend payouts may vary based on several risk factors.
Baxter International reported fourth-quarter sales of $3.2 billion, a 5% year-over-year increase, despite a flat U.S. market. International sales rose 8%, driven by Acute Therapies demand during COVID-19. Fourth-quarter net income was $168 million or $0.33 per share, influenced by special items totaling $244 million. For 2020, sales reached $11.7 billion, up 3%, with net income of $1.1 billion. The company expects 2021 sales growth of 7-8% and adjusted earnings per share of $3.35 to $3.43. Baxter remains committed to shareholder value and innovation amidst ongoing challenges.
Baxter International (NYSE:BAX) will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 10:40 a.m. Eastern Time. Jay Saccaro, the company’s CFO, is scheduled to speak. A live webcast of the presentation will be available on www.baxter.com and can be replayed until May 25, 2021. Baxter has a legacy of over 85 years in transforming healthcare through innovations in critical care, nutrition, renal, and surgical products, serving patients in over 100 countries.
Baxter International has announced an agreement with Novavax to provide sterile manufacturing services for the COVID-19 vaccine candidate NVX-CoV2373. This partnership aims to support commercial-scale manufacturing for distribution in the UK and Europe. The facility in Halle/Westfalen, Germany, will ensure compliance with cGMP standards. Currently in phase 3 trials, the vaccine has not yet received authorization. Novavax's vaccine utilizes recombinant nanoparticle technology, aiming to provide a safe and effective solution amid the ongoing pandemic.
Baxter International Inc. (NYSE:BAX) announced a conference call to discuss its fourth-quarter 2020 financial results scheduled for February 4, 2021, at 7:30 a.m. Central Time. Interested participants can pre-register using the provided link or access the webcast via Baxter’s website. The call will be recorded and is copyrighted material.
Baxter has been a trusted provider of healthcare products for over 85 years, offering critical care, nutrition, and renal products in over 100 countries.
Baxter International (NYSE:BAX) will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. CEO José Almeida is scheduled to speak on January 11, 2021, at 9:10 a.m. ET. Investors can access the live webcast and slides at www.baxter.com, with replays available until February 11, 2021. Baxter has been a vital player in healthcare for over 85 years, providing critical care, nutrition, and surgical products across more than 100 countries.
Baxter International (NYSE:BAX) partners with AdventHealth Tampa to implement the Vital Edge program, expected to save the hospital approximately $200,000 annually. This program focuses on intraoperative hemostasis management, aiming to enhance clinical efficacy, operational efficiency, and financial performance. The initiative responds to growing concerns over surgical bleeding, which complicates patient outcomes and increases costs. Baxter's collaboration with AdventHealth aims to optimize the use of hemostatic agents, providing educational resources and data-driven insights for better hospital practices.
Baxter International Inc. (NYSE:BAX) announced a $50 million expansion of its sterile fill/finish manufacturing facilities in Bloomington, Indiana. This development, funded through Baxter and client investments, includes a new 25,000 sq. ft. warehouse, filling lines, and automated inspection lines. Construction is ongoing, with completion expected in 2021 and manufacturing set for 2022. The expansion will create approximately 100 new jobs at the site, enhancing Baxter's capabilities in sterile contract manufacturing for over 25 pharmaceutical companies.
Baxter International Inc. (NYSE:BAX) has received FDA clearance for its Homechoice Claria automated peritoneal dialysis (APD) system, featuring the Sharesource connectivity platform. This innovative system is designed for both adult and pediatric patients, enhancing remote patient management and promoting home dialysis growth. With over 6 million home dialysis treatments facilitated by Sharesource in the U.S., the new system aims to improve patient education and care efficiency. Homechoice Claria is slated for U.S. availability in the coming weeks.
FAQ
What is the current stock price of Baxter International (BAX)?
What is the market cap of Baxter International (BAX)?
What does Baxter International Inc. specialize in?
What was the impact of Baxter's acquisition of Hillrom?
What products does Baxter offer for kidney failure patients?
What are some of Baxter's injectable therapies?
What surgical products does Baxter provide?
What is Baxter's plan for its renal care segment?
How does Baxter contribute to global healthcare access?
How does Baxter ensure continuous innovation?
What are some of the digital solutions offered by Baxter?
What is Baxter's commitment to patient care?
